Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma

Abstract Background Immunotherapy is an important treatment in oncology, but only a fraction of patients with head and neck squamous cell carcinoma (HNSCC) benefit from it. Therefore, the aim of this study was to identify predictive biomarkers of immunotherapy response for HNSCC in order to improve...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xuanli Xu, Rongrong Li, Lin Zhang, Guopei Zhu, Dandan Ren, Lijia Wu, Xiaoli Gong
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Head and neck squamous cell carcinoma Immunotherapy Prognosis Efficacy Pathology RB1-214
Acceso en línea:	https://doaj.org/article/7c767f7a3a1e4b3fb853351e46948a2e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7c767f7a3a1e4b3fb853351e46948a2e
record_format	dspace
spelling	oai:doaj.org-article:7c767f7a3a1e4b3fb853351e46948a2e2021-11-28T12:37:11ZIdentification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma10.1186/s13000-021-01147-71746-1596https://doaj.org/article/7c767f7a3a1e4b3fb853351e46948a2e2021-11-01T00:00:00Zhttps://doi.org/10.1186/s13000-021-01147-7https://doaj.org/toc/1746-1596Abstract Background Immunotherapy is an important treatment in oncology, but only a fraction of patients with head and neck squamous cell carcinoma (HNSCC) benefit from it. Therefore, the aim of this study was to identify predictive biomarkers of immunotherapy response for HNSCC in order to improve treatment outcomes. Methods Survival analyses and comparative efficacy evaluation were performed to investigate prognostic and therapeutic impact factors in patients with advanced HNSCC following immunotherapy, and to examine the effects of factors including gene mutations, tumor mutational burden (TMB), mutant-allele tumor heterogeneity (MATH), and immune cell infiltration on the survival and efficacy. Results Anti-PD-1 treatment led to a prolonged overall survival (OS) in HNSCC patients with gene mutations compared with those without the mutations, while no significant difference in the OS was found between the two groups of patients. And no marked association between the MATH value and OS was detected in HNSCC patients, whereas patients with either high TMB scores in tissues and blood or high immune cell infiltration displayed a significantly longer OS. Further analysis with efficacy as the primary endpoint revealed no significant differences in the tissue TMB, blood TMB, and MATH value between the patients who responded to immunotherapy and those who did not. Moreover, no significant differences in the expression percentages of positive immune cells in tumor, stroma, and total regions were identified between the above two groups of patients. Conclusion HNSCC is characterized by high mutation rate, high mutation burden, and high level of immune cell infiltration, and a subset of HNSCC patients respond to immunotherapy. Here, we showed that high mutation burden and immune cell infiltration may improve the prognosis of HNSCC patients with immunotherapy, while there was no remarkable effect on the efficacy.Xuanli XuRongrong LiLin ZhangGuopei ZhuDandan RenLijia WuXiaoli GongBMCarticleHead and neck squamous cell carcinomaImmunotherapyPrognosisEfficacyPathologyRB1-214ENDiagnostic Pathology, Vol 16, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Head and neck squamous cell carcinoma Immunotherapy Prognosis Efficacy Pathology RB1-214
spellingShingle	Head and neck squamous cell carcinoma Immunotherapy Prognosis Efficacy Pathology RB1-214 Xuanli Xu Rongrong Li Lin Zhang Guopei Zhu Dandan Ren Lijia Wu Xiaoli Gong Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma
description	Abstract Background Immunotherapy is an important treatment in oncology, but only a fraction of patients with head and neck squamous cell carcinoma (HNSCC) benefit from it. Therefore, the aim of this study was to identify predictive biomarkers of immunotherapy response for HNSCC in order to improve treatment outcomes. Methods Survival analyses and comparative efficacy evaluation were performed to investigate prognostic and therapeutic impact factors in patients with advanced HNSCC following immunotherapy, and to examine the effects of factors including gene mutations, tumor mutational burden (TMB), mutant-allele tumor heterogeneity (MATH), and immune cell infiltration on the survival and efficacy. Results Anti-PD-1 treatment led to a prolonged overall survival (OS) in HNSCC patients with gene mutations compared with those without the mutations, while no significant difference in the OS was found between the two groups of patients. And no marked association between the MATH value and OS was detected in HNSCC patients, whereas patients with either high TMB scores in tissues and blood or high immune cell infiltration displayed a significantly longer OS. Further analysis with efficacy as the primary endpoint revealed no significant differences in the tissue TMB, blood TMB, and MATH value between the patients who responded to immunotherapy and those who did not. Moreover, no significant differences in the expression percentages of positive immune cells in tumor, stroma, and total regions were identified between the above two groups of patients. Conclusion HNSCC is characterized by high mutation rate, high mutation burden, and high level of immune cell infiltration, and a subset of HNSCC patients respond to immunotherapy. Here, we showed that high mutation burden and immune cell infiltration may improve the prognosis of HNSCC patients with immunotherapy, while there was no remarkable effect on the efficacy.
format	article
author	Xuanli Xu Rongrong Li Lin Zhang Guopei Zhu Dandan Ren Lijia Wu Xiaoli Gong
author_facet	Xuanli Xu Rongrong Li Lin Zhang Guopei Zhu Dandan Ren Lijia Wu Xiaoli Gong
author_sort	Xuanli Xu
title	Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma
title_short	Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma
title_full	Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma
title_fullStr	Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma
title_full_unstemmed	Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma
title_sort	identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma
publisher	BMC
publishDate	2021
url	https://doaj.org/article/7c767f7a3a1e4b3fb853351e46948a2e
work_keys_str_mv	AT xuanlixu identificationoffactorsrelatedtoimmunotherapyefficacyandprognosisinpatientswithadvancedheadandnecksquamouscellcarcinoma AT rongrongli identificationoffactorsrelatedtoimmunotherapyefficacyandprognosisinpatientswithadvancedheadandnecksquamouscellcarcinoma AT linzhang identificationoffactorsrelatedtoimmunotherapyefficacyandprognosisinpatientswithadvancedheadandnecksquamouscellcarcinoma AT guopeizhu identificationoffactorsrelatedtoimmunotherapyefficacyandprognosisinpatientswithadvancedheadandnecksquamouscellcarcinoma AT dandanren identificationoffactorsrelatedtoimmunotherapyefficacyandprognosisinpatientswithadvancedheadandnecksquamouscellcarcinoma AT lijiawu identificationoffactorsrelatedtoimmunotherapyefficacyandprognosisinpatientswithadvancedheadandnecksquamouscellcarcinoma AT xiaoligong identificationoffactorsrelatedtoimmunotherapyefficacyandprognosisinpatientswithadvancedheadandnecksquamouscellcarcinoma
_version_	1718407898639368192

Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma

Ejemplares similares